Botanical species · safety record

Tagetes erecta

The EFSA Compendium of Botanicals holds 13 constituent measurements for Tagetes erecta. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Tagetes erecta L.

13Constituent measurements

0Safety records

3Cited sources

252Licensed products (Canada)

Also recorded as

Tagetes patula L.

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 252 licensed products naming Tagetes erecta as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

Source material stated

African marigold- Flower
Flower
Flower extract
Marigold flower
Marigold flower (Tagetes erecta)
Marigold flower (oleoresin of Tagetes erecta L. (Asteraceae))
Marigold flower petals
Marigold flower- Oleoresin

What the records describe

Constituents measured

Plant parts

Preparations

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Alpha-terthienyl	Roots and other underground parts	Solvent extraction	3.86 Percent Area	GC-MS	Resolve DOI
Cis-ocimenone	Leaves	Essential oil	13 Percent	Gaschromatography (GC)	Resolve DOI
Furfural	Roots and other underground parts	Solvent extraction	2.87 Percent Area	GC-MS	Resolve DOI
Hydroxymethylfurfural	Roots and other underground parts	Solvent extraction	21.81 Percent Area	GC-MS	Resolve DOI
L-piperitone	Leaves	Essential oil	8.8 Percent	Mass Spectroscopy and hyphenated methods without chromatography	Resolve DOI
P-mentha-1,4(8)-dien-3-one	Leaves	Essential oil	9.7 Percent	Mass Spectroscopy and hyphenated methods without chromatography	Resolve DOI
Tagetone	Leaves	Essential oil	≥ 6.9 Percent	Gaschromatography (GC)	Resolve DOI
Tagetone	Leaves	Essential oil	≤ 11.8 Percent	Gaschromatography (GC)	Resolve DOI
Verbenone	Leaves	Essential oil	9.7 Percent	Gaschromatography (GC)	Resolve DOI
1,4-naphthoquinone	Flower	Essential oil	6.5 Percent	GC-MS	No resolvable identifier
L-piperitone	Flower	Essential oil	13.4 Percent	GC-MS	No resolvable identifier
Menthone	Flower	Essential oil	1.2 Percent	GC-MS	No resolvable identifier
P-mentha-1,4(8)-dien-3-one	Flower	Essential oil	4.8 Percent	GC-MS	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Martinez, Rossana., Diaz, Beth., Vasquez, Luis., Compagnone, Reinaldo S., Tillett, Stephen., Canelon, Dilsia J., Torrico, Fatima., Suarez, Alirica I. Chemical Composition of Essential Oils and Toxicological evaluation of Tagetes erecta and Tagetes patula from Venezuela . Journal of essential oil bearing plants, 2009, vol. 12, no. 4, p. 476-481.
de Oliveira, Pollyanna Francielli., Alves, Jacqueline Morais., Damasceno, Jaqueline Lopes., Machado Oliveira, Renata Aparecida., Dias, Herbert Junior., Miller Crotti, Antonio Eduardo., Tavares, Denise Crispim. Cytotoxicity screening of essential oils in cancer cell lines. Revista brasileira de farmacognosia-brazilian journal of pharmacognosy, 2015, vol. 25, no. 2, p. 183-188. DOI
Kumar, A., Chahal, K.K., Kataria, D. Comparison of chemical composition of root and rhizosphere soil extracts of Tagetes patula L.: GC-MS analysis. Asian journal of chemistry, 2017, vol. 29, no. 4, p. 797-800. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature